Merck & Co., Inc. (MRK)

Market Cap	242.04B
Revenue (ttm)	63.17B
Net Income (ttm)	12.15B
Shares Out	2.53B
EPS (ttm)	4.78
PE Ratio	20.02
Forward PE	11.16
Dividend	$3.24 (3.39%)
Ex-Dividend Date	Dec 16, 2024

Volume	12,805,035
Open	95.96
Previous Close	96.24
Day's Range	95.15 - 96.98
52-Week Range	94.48 - 134.63
Beta	0.40
Analysts	Buy
Price Target	124.64 (+30.27%)
Earnings Date	Feb 4, 2025

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2000
• Employees: 72,000
• Stock Exchange: NYSE
• Ticker Symbol: MRK
• Website: https://www.merck.com

Financial Performance

In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.

Analyst Forecast

According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $124.64, which is an increase of 30.27% from the latest price.

Price Target

$124.64

(30.27% upside)

Analyst Consensus: Buy